Synergy between two calcium channel blockers, verapamil and fantofarone (SR33557), in reversing chloroquine resistance in Plasmodium falciparum

Biochemical Pharmacology

Volumn 55, Issue 4, 1998, Pages 433-440

  Adovelande, Jacques ^a   Delèze, Jean ^b   Schrével, Joseph ^a  

^a MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

^b CNRS   (France)

Author keywords

Calcium channel blockers; Chloroquine; Drug resistance reversal; Fantofarone (SR33557); Malaria; Plasmodium falciparum; Verapamil

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CHLOROQUINE; FANTOFARONE; VERAPAMIL;

ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESISTANCE; MALARIA; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ANIMALS; ANTIMALARIALS; CALCIUM CHANNEL BLOCKERS; CHLOROQUINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; DRUG SYNERGISM; HUMANS; INDOLIZINES; MALARIA, FALCIPARUM; PHENETHYLAMINES; PLASMODIUM FALCIPARUM; VERAPAMIL;

EID: 0032520193     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00482-6     Document Type: Article

References (45)

1. Ginsburg H, Minireview. Enhancement of the antimalarial effect of chloroquine on drug-resistant parasite strains: a critical examination of the reversal of multidrug resistance. Exp Parasitol 73: 227-232, 1991.
2. Karcz S and Cowman AF, Similarities and differences between the multidrug resistance phenotype of mammalian tumor cells and chloroquine resistance in Plasmodium falciparum. Exp Parasitol 73: 233-240, 1991.
3. Hayes JD and Wolf CR, Molecular mechanisms of drug resistance. Biochem J 272: 281-295, 1990.
4. Endicott JA and Ling V, The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann Rev Biochem 58: 137-171, 1989.
5. Safa AR, Photoaffinity labelling of the multidrug resistance-related P-glycoprotein with photoactive analogs of verapamil. Proc Nati Acad Sci USA 85: 7187-7191, 1988.
6. Fojo A, Akiyama S, Gottesman M and Pastan 1, Reduced drug accumulation in multiple drug resistant human KB carcinoma cell lines. Cancer Res 45: 3002-3007, 1985.
7. Rogan AM, Hamilton TC, Young RC, Klecker RW and Ozols RF, Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224: 994-996, 1989.
8. Wilson CM, Serrano AE, Wasley A, Bogenschultz MP, Shankar A and Wirth DF, Amplification of a gene related to mammalian mdr genes in drug-resistant Plasmodium falciparum. Science 244: 1184-1186, 1989.
9. Foote SJ, Thompson JK, Cowman AF and Kemp DJ, Amplifi-cation of the multidiug resistance gene in some chloroquine-resistant isolates of P. falciparum. Cell. 57: 921-930, 1989.
10. Foote SJ, Kyle DE, Martin RK, Oduola AM, Forsyth K, Kemp DJ and Cowman AF, Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum. Nature 345: 255-258, 1990.
11. Wellems TE, Paton LJ, Gluzman IY, Rosario do VE, Gwadz RW, Walker-Jonah A and Krogstad DJ, Chloroquine resistance not linked to mdr-like genes in a Plasmodium falciparum cross. Nature 345: 253-255, 1990.
12. Martin KM, Oduola AMJ and Milhous WK, Reversal of chloroquine resistance in Plosmodium falciparum by verapamil. Science 235: 899-901, 1987.
13. Ramuz H, Schmutz W and Huber R, Ro 11-2933, a potential drug in the treatment of cancer and malaria: synthesis and physicochemical properties; potential metabolites. Eur J Med Chem 24: 493-496, 1989.
14. Kyle DE, Oduola A, Martin SK and Milhous WK, Plasmodium falciparum: modulation by calcium antagonists of resistance to chloroquine, desethylchloroquine, quinine and quinidine in vitro. Trans R Soc Trop Med Hyg 84: 474-478, 1990.
15. Deloron P, Basko LK, Dubois B, Gaudin C, Clavier F, Le Bras J and Verdier F, In vitro and in vivo potentiation of chloroquine against malaria parasites by an enantiomer of amlodipine. Antimicrob Agents Chemother 35: 1338-1342, 1991.
16. Pietrobon D, Di Virgillio and Pozzan T, Structural and functional aspects of calcium homeostasis in eukaryotic cells. Eur J Biochem 193: 599-622, 1990.
17. Berridge MJ, Inositol phosphate and calcium signalling. Nature 361: 315-325, 1993.
18. Nokin P, Clinet M, Beaufort P, Meysmans L, Laruel R and Chatelain P, SR 33557, a novel calcium entry blocker. II Interactions with 1,4-dihydropyridine, phenylalkylamine and benzothiazepine binding sites in rat heart sarcolemmal membranes. J Pharmacol Exp Therap 255: 600-607, 1990.
19. 2+ channel activity and excitation-contraction coupling in skeletal muscle. Pflugers Arch 419: 651-656, 1991.
20. 2+ channels: Identification of receptor sites and analysis of its mode of action. Mol Pharmacol 35: 766-773, 1989.
21. Chatelain P and Gubin J, Aminoalkoxybenzenesulfonyl heterocyclic compounds, a novel class of calcium channel antagonists. Structure-activity relationship with a focus on fantofarone, SR 33557. Drugs Future 18: 817-832, 1993.
22. Jaffrézou JP, Herbert JM, Levade T, Gau MN, Chatelain P and Laurent G, Reversal of multidrug resistance by calcium channel blocker SR33557 without photoaffinity labelling of P-glycoprotein. J Biol Chem 266: 19858-19864, 1991.
23. Adovelande J, Bastide B, Délèze J and Schrével J, Cytosolic free calcium in Piosmodium falciparum- infected erythrocytes and the effect of verapamil: a cytofluorimetric study. Exp Parasitol 76: 247-258, 1993.
24. Kramer RA, Zakher J and Kim G, Role of the glutathione redox cycle in acquired and de novo multidrug resistance. Science 241: 694-697, 1988.
25. Hait WN and Aftab DT, Rational design and pre-clinical pharmacology of drugs for reversing multidrug resistance. Biochem Pharmacol 43: 103-107, 1992.
26. Trager W and Jensen JB, Human malaria parasites in continuous culture. Science 193: 673-677, 1976.
27. Desjardins RE, Canfield CJ, Haynes JD and Chulay JD, Quantitative assessment of antimalarial activity in vitro by a semi-automated microdilution technique. Antimicrob Agents Chemother 16: 710-718, 1979.
28. Berenbaum MC, A method for testing for synergy with any number of agents. J Infect Dis 137: 122-130, 1978.
29. Slater AFG, Chloroquine: Mechanism of drug action and resistance in Plasmodium falciparum. Pharmac Ther 57: 203-235, 1993.
30. Krogstad DJ, Gluzman I.Y, Kyle DE, Oduola AM, Martin SK, Mihous WK and Schlessinger PH, Efflux of chloroquine from Plasmodium falciparum: mechanism of chloroquine resistance. Science 238: 1283-1285, 1987.
31. Cornwell MM, Safa AR, Felsted RL, Gottensman MM and Pastan I, Membrane vesicles from multidrug-resistant human cancer cells contain a specific 150- to 170-kDa protein detected by photoaffinity labeling. Proc Natl Acad Sci USA 83: 3847-3850, 1986.
32. Hyde SC, Emsley P, Hartshorn MJ, Mimmarck MM, Gileadi U, Pearce SR, Gallagher MP, Gill DR, Hubbard RE and Higgings CF, Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 346: 362-365, 1990.
33. Bray PG, Howells RE, Ritchie GY and Ward SA, Rapid chloroquine efflux in both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum: A correlation of chloroquine sensitivity with energy-dependent drug accumulation. Biochem Pharmacol 44: 1317-1324, 1992.
34. Martiney JA, Cerami A and Slater AFG, Verapamil reversal of chloroquine resistance in the malaria parasite Plasmodium falciparum is specific for resistant parasites and independent of the weak base effect. J Biol Chem 270: 22393-22398, 1995.
35. Ginsburg H and Stein WD, Kinetic modelling of chloroquine uptake by malaria-infected erythrocytes. Biochem Pharmacol 41: 1463-1470, 1991.
36. Sanchez CP, Wunsch S and Lanzer M, Identification of a chloroquine importer in Plasmodium falciparum: Difference in import kinetics are genetically linked with the chloroquine-resistant phenotype. J Biol Chem 272: 2652-2658, 1997.
37. Ye Z and Van Dyke K, Reversal of chloroquine resistance in falciparum malaria independent of calcium channels. Biochem Biophys Res Comm 155: 476-481, 1988.
38. Lelong IH, Guzikowski AP, Haugland RP, Pastan I, Gottesman MM and Willingham MC, Fluorescent verapamil derivative for monitoring activity of the multidrug transporter Mol Pharmacol 40: 490-494, 1991.
39. Cornwell MM, Pastan I and Gottesman MM, Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 262: 2166-2170, 1987.
40. Raderer M and Scheithauer W, Clinical trials of agents that reverse multidrug resistance: literature review. Cancer 72: 3553-3563, 1993.
41. Caudell J, Valle V and Soler M, Acute intoxication with verapamil. Chest 75: 200-201, 1979.
42. Ford JM, Bruggeman E, Pastan I, Gottesman MM and Hait WN, Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res 50: 1748-1756, 1990.
43. Hu XF, Martin TJ, Bell DR, Luise M and Zalcberg JR, Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res 50: 2953-2957, 1990.
44. Osnann K, Sweet P and Slater LM, Synergistic interaction of cyclosporin A and verapamil on vincristine and doxorubicin resistance in multidrug-resistant human leukemia cells in vitro. Cancer Chemother Pharmacol 30: 152-154, 1992.
45. Lehnert M, Dalton WS, Roe D, Emerson S and Salmon SE, Synergistic inhibition by verapamil and quinine of P-glyco-protein-mediated multidrug resistance in a human myeloma cell line model. Blood 77: 348-354, 1991.